From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Identifying and unifying sources of margin erosion – including commercial, 340B program, and reversals – in today’s complex healthcare ecosystem can be challenging. Current data resources do not provide a unified view of revenue streams.
Expanded Use of 340B Purchasing Increases Abuse Risk The rapid growth in the 340B purchasing program can lead to losses from program abuse practices including diversion, misclassified patients, orphan drug violations, duplicate discounts, or returns arbitrage.
Gaps in Traditional Datasets Limit Visibility Traditional syndicated datasets contain gaps and can be difficult to align with chargeback data to identify revenue loss.
Missing Chargebacks Create Risk Most manufacturers struggle to integrate contracted business (chargebacks) with commercial business and many lack a method to identify when wholesalers fail to submit reverse chargebacks for product returns, risking revenue loss.
Market Access Solutions
HCO Analytics delivers enriched datasets that leverage IntegriChain’s best-in-class channel master data and analytics to deliver an unparalleled unified view of how patients access products. These datasets offer an unparalleled, unified view of commercial and 340B transactions across all covered entities, sites of care, owned pharmacies, and contract pharmacies to address today’s revenue analysis data challenges.
Sales and Marketing teams can analyze 340B sales growth and channel mix changes and track movements of products to lower-cost sites of care.
Finance and Compliance teams can build reports to identify 340B and commercial units by sites of care and pharmacies and highlight suspicious activity by account and compare against baseline for key products.
Sales and Marketing teams can establish a dashboard of key accounts to track trends in units sold, sales mix, and returns by site or pharmacy and orphan drug usage at ACA expansion sites.
Finance and Compliance teams can understand the breadth and history of possible 340B program abuse, using this knowledge to inform settlement decisions.
Finance and Compliance teams can crosswalk 867 and paid chargeback claims to identify misclassified records and report data accuracy discrepancies to distributors.
Finance and Compliance teams can prioritize discrepancies and validate missing returns against invoices.
